Lofarma S.p.a.

Consiglio Nazionale Delle Ricerche

Gruppo Lepetit S.p.a.

Laboratorio Farmaceutico Lofarma S.r.l.

Giovanni Mistrello

Daniela Roncarolo

Stefania Zanotta

Paolo Falagiani

Dario Zanoni

Monica Sturaro

Angelo Viotti

Carolina Coronelli

Angelo Borghi

Giorgio Pirali

Oreste Brenna

A method of making and a modified allergen having reduced allergenicity and preserved immunogenicity compared to corresponding native allergenic material. The preserved immunogenicity is elicited by a IgG-mediated antibody response, all or part of the primary amine groups of the lysine residues of the native allergenic material are functionalized with carbamoyl or thiocarbamoyl moieties, and all or part of the primary amine groups of the arginine residues of the carbamoyl- or thiocarbamoyl functionalized allergenic material are further functionalized with dialdehyde or diketal moieties. The raw allergenic material is selected from the group consisting of DP mites extract, Der p1, ovalbumin and Lipid Transfer Protein (LTP), the average percentage of modified primary amine groups of the lysine ranges between 75% and 100%; and the average percentage of the substituted arginine residues ranges between 25% and 10%.

Allergoids derived from allergenes

Disclosed are hypoallergenic variants of Mal d 1, the major allergen from, and the uses thereof in the treatment of allergic diseases.

Hypoallergenic variants of mal d 1, the major allergen from malus domestica

Disclosed are hypoallergenic variants of Phl p 5, the major allergen from, and the uses thereof in the treatment of allergic diseases.

[object Object]

The invention provides hypoallergenic variants of Bet v 1 major allergen fromplant pollen and the use thereof for the preventive or therapeutic treatment of allergic diseases.

The present invention concerns the preparation of purified allergens and allergoids, both derived from whole bee venom, for the desensitization (immunotherapy) of subjects affected by a specific allergy. In particular, the present invention concerns a preparation for immunotherapy based on purified bee venom, characterized in that said bee venom is essentially mellitin-free. In addition, the preparation of a monomeric allergoid obtainable through the carbamylation or thiocarbamylation reaction of said mellitin-free bee venom, is described. Said allergoid, being characterized by reduced IgE-binding activity, may be a safer and more effective candidate for specific immunotherapy.

Allergens and allergoids from bee venom

The invention provides hypoallergenic variants of Bet v 2 major allergen fromplant pollen and the use thereof for the preventive or therapeutic treatment of allergic diseases.

Hypoallergenic variants of the major allergen Ph1 p 1 ofplants and their use in the therapy of the allergic diseases is disclosed.

Variants of Phleum pratense allergenic proteins

Variants of allergens of species with reduced allergenic activity.

Variants of allergenic proteins of the group 2 of dermatophagoides

Chemically modified allergens, whose allergenic activity is reduced with respect to that of the corresponding native allergenic material, which are capable of inducing specific antibodies addressed towards said native allergenic material, wherein a portion of the primary amino groups of the protein molecule of the native allergen are chemically modified so as to give simple or substituted carbamylic amino groups, or substituted thiocarbamylic amino groups, or possibly substituted guanidino groups, and process for the production thereof. The allergens so modified are not polymerized with each other, they are soluble in water media, they are resistent to tryptic hydrolysis and they show particularly suitable for being administered in hyposensitizing therapeutic treatments.

Chemically modified allergens and process for the preparation thereof

A new antibiotic, designated S/433, is disclosed which is produced in a microbiological fermentation under controlled conditions using a new strain of Streptomyces. This new antibiotic is active against gram-positive and gram-negative bacteria and is also active in inhibiting the growth of transplanted tumors.

Growing community of inventors

Milan, Italy

Giovanni Mistrello